Featured
Brolucizumab shows promise over aflibercept for diabetic macular edema in meta-analysis
A recent study that compared 2 anti-vascular endothelial growth factor drugs for treating diabetic macular edema (DME) found that brolucizumab (Beovu, Novartis) was non-inferior in functional outcomes and superior to aflibercept (Eylea, Regeneron Pharmaceuticals) in anatomic parameters,1 according to first author Leonardo B. Justino from the Division of Medicine, Federal University of Santa Catarina, Florianópolis,…
RETINA NEWS SPOTLIGHT
Alcon recalls one lot of Systane single-use eye drops due to fungal contamination
December 27, 2024 1 min read Alcon Laboratories announced the voluntary recall of one lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, following a consumer complaint that led to the discovery of fungal contamination in the drops. “Investigation of this event is
Continue Reading Alcon recalls one lot of Systane single-use eye drops due to fungal contamination
Alert: Alcon voluntarily recalls Systane Ultra PF lot due to potential fungal contamination
In response to a report of foreign material found in a sealed vial, Alcon Laboratories has initiated a voluntary recall of Lot 10101 of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count.Alcon evaluated a consumer complaint of foreign material observed inside a sealed…
Eyecare wrapped: Top stories from Modern Retina in 2024
In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ophthalmology, and retina conferences. Let’s look back on some of the top stories of the year as we gear up for an incredible 2025.GA and AMDAge-related macular…
Continue Reading Eyecare wrapped: Top stories from Modern Retina in 2024
Part 6: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.Video Transcript:Editor’s note: The below transcript has been lightly edited for clarity.Fatemah Rajaii, MD, PhD:I think it would be awesome if we had a way to…
Study: Thelazia callipaeda infection in a 41-year-old female patient
Thelaziasis, an ocular parasitic infection caused by Thelazia callipaeda, poses unique diagnostic and therapeutic challenges for ophthalmologists.This zoonotic disease, transmitted by Drosophilid flies, is associated with a spectrum of ocular symptoms ranging from mild irritation to severe inflammation. Here, we present a case of Thelazia callipaeda…
Continue Reading Study: Thelazia callipaeda infection in a 41-year-old female patient
Beyond VEGF: A Next-generation therapies aim to enhance vision and quality of life in neovascular AMD
VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to be FDA approved, was introduced more than 18 years ago. Despite the introduction of additional nAMD therapies over the years, visual outcomes obtained have…
Explore
Eyecare wrapped: Top stories from Modern Retina in 2024
In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ophthalmology, and retina…
Continue Reading Eyecare wrapped: Top stories from Modern Retina in 2024
Part 6: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.Video Transcript:Editor’s…
Study: Thelazia callipaeda infection in a 41-year-old female patient
Thelaziasis, an ocular parasitic infection caused by Thelazia callipaeda, poses unique diagnostic and therapeutic challenges for ophthalmologists.This zoonotic disease, transmitted by Drosophilid…
Continue Reading Study: Thelazia callipaeda infection in a 41-year-old female patient